Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: METTL3 regulates RIG-I expression through m6A modification and YTHDF2 binds to the METTL3-mediated m6A modification of DDX58 mRNA. (A, B) MeRIP- qPCR analysis was used to assess the m6A levels of DDX58 mRNA in METTL3-overexpressing A549 (A) and H460 (B) cells compared with negative control. The enrichment of m6A in each group was calculated by m6A-IP/input and IgG-IP/input. (C, E) The protein levels of RIG-I in knockdown of m6A “readers” (YTHDF1,YTHDF2 and YTHDF3) A549 (C) and H460 (E) cells. (D, F) The protein levels of RIG-I were measured by western blot in the following groups of A549 (D) and H460 (F) cells. Control, shCon + METTL3 and shYTHDF2 + METTL3. (G, H) RNA binding protein immunoprecipitation (RIP) assays were performed using an YTHDF2 antibody or IgG in METTL3-OV A549 (G) and H460 (H) cells. The primer targeting the m6A-modified region of DDX58 mRNA was used in the RIP-qPCR. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Expressing, Modification, Negative Control, Knockdown, Western Blot, Control, RNA Binding Assay, Immunoprecipitation

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: METTL3 regulates RIG-I expression through m6A modification and YTHDF2 binds to the METTL3-mediated m6A modification of DDX58 mRNA. (A, B) MeRIP- qPCR analysis was used to assess the m6A levels of DDX58 mRNA in METTL3-overexpressing A549 (A) and H460 (B) cells compared with negative control. The enrichment of m6A in each group was calculated by m6A-IP/input and IgG-IP/input. (C, E) The protein levels of RIG-I in knockdown of m6A “readers” (YTHDF1,YTHDF2 and YTHDF3) A549 (C) and H460 (E) cells. (D, F) The protein levels of RIG-I were measured by western blot in the following groups of A549 (D) and H460 (F) cells. Control, shCon + METTL3 and shYTHDF2 + METTL3. (G, H) RNA binding protein immunoprecipitation (RIP) assays were performed using an YTHDF2 antibody or IgG in METTL3-OV A549 (G) and H460 (H) cells. The primer targeting the m6A-modified region of DDX58 mRNA was used in the RIP-qPCR. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Expressing, Modification, Negative Control, Knockdown, Western Blot, Control, RNA Binding Assay, Immunoprecipitation

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: Knockdown of RIG-I promotes A549 and H460 cells proliferation and migration, and IRF9 or IFI6 are downstream proteins regulated by RIG-I. (A, B) Colony formation was analyzed to detect the proliferation in control and RIG-I-KD A549 (A) or H460 (B) cells. (C, D) Transwell assays showed the ability of migration in control and RIG-I-KD A549 (C) or H460 (D) cells. (E) Heat map of RNA- seq to identify the genes regulated by METTL3 knockdown. (F, G) Westrern blot to detected RIG-I, IRF9 and IFI6 protein levels of control and METTL3-KD A549 (F) or H460 (G) cells. (H, I) Shown are RIG-I, IRF9 and IFI6 protein levels in A549 (H) or H460 (I) cells treated with DMSO and Inarigivir soproxil (5 μM) for 48 h. The data represents the mean±SD from three independent experiments.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Knockdown, Migration, Control, RNA Sequencing

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: N6-methyladenosine modification and the expression of METTL3 was increased in NSCLC. (A, B) The mRNA level of METTL3 was analyzed in LUAD (A) or LUSC (B) tumors tissues and paired normal tissues according to UALCAN ( https://ualcan.path.uab.edu/ ). (C) Kaplan-Meier disease-free survival analysis of patients with NSCLC according to GEPIA ( http://gepia2.cancer-pku.cn/ ). (D) Dot blot to detected the m6A levels of poly(A) + RNAs isolated from total RNA of Beas-2B, A549, NCI-H460 and NCI-H1299 cells. (E) METTL3 expression at protein level was detected by western blot in Beas-2B, A549, NCI-H460 and NCI-H1299 cells. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Modification, Expressing, Dot Blot, Isolation, Western Blot

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: Knockdown of METTL3 suppressed A549 and H460 cells proliferation and migration. (A, B) Cell Counting Kit-8 assay assessed the viability of A549 (A) and H460 (B) cells in the presence or absence of METTL3 knockdown. (C, D) Colony formation assays were performed in control and METTL3-KD A549 (C) or (D) H460 cells. (E, F) Wound healing assay showed the ability of migration in control and METTL3-KD A549 (E) or H460 (F) cells. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Knockdown, Migration, Cell Counting, Control, Wound Healing Assay

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: RIG-I was identified as a downstream target of METTL3. (A) Reatome annotations analysis (left) and KEGG pathway analysis (right) after METTL3 knockdown in A549 cells by RNA-seq. (B, C) RIG-I protein levels in control and METTL3- KD A549 (B) or H460 (C) cells by western blot analysis. (D, E) The mRNA expression of RIG-I in control and METTL3- KD A549 (D) or H460 (E) cells was detected by qRT - PCR. (F) The protien levels of the RIG-I-MAVS signaling pathway was detected after METTL3 knockdown in A549 and H460 cells. (G, H) The protein levels of RIG-I in METTL3-OV A549 (G) or H460 (H) cells by western blot analysis. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Knockdown, RNA Sequencing, Control, Western Blot, Expressing, Quantitative RT-PCR

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: METTL3 regulates RIG-I expression through m6A modification and YTHDF2 binds to the METTL3-mediated m6A modification of DDX58 mRNA. (A, B) MeRIP- qPCR analysis was used to assess the m6A levels of DDX58 mRNA in METTL3-overexpressing A549 (A) and H460 (B) cells compared with negative control. The enrichment of m6A in each group was calculated by m6A-IP/input and IgG-IP/input. (C, E) The protein levels of RIG-I in knockdown of m6A “readers” (YTHDF1,YTHDF2 and YTHDF3) A549 (C) and H460 (E) cells. (D, F) The protein levels of RIG-I were measured by western blot in the following groups of A549 (D) and H460 (F) cells. Control, shCon + METTL3 and shYTHDF2 + METTL3. (G, H) RNA binding protein immunoprecipitation (RIP) assays were performed using an YTHDF2 antibody or IgG in METTL3-OV A549 (G) and H460 (H) cells. The primer targeting the m6A-modified region of DDX58 mRNA was used in the RIP-qPCR. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Expressing, Modification, Negative Control, Knockdown, Western Blot, Control, RNA Binding Assay, Immunoprecipitation

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: RIG-I knockdown reverses the proliferation and migration of METTL3 - KD A549 or H460 cells. (A, B) CCK-8 assays were analyzed to detect the proliferation in the following groups of A549 (A) and H460 (B) cells. (C, D) Colony formation was analyzed in the following groups of A549 (C) and H460 (D) cells. (E, F) Transwell assays showed the ability of migration in the following groups of A549 (E) and H460 (F) cells. Control, shMETTL3, shMETTL3+shRIG-I. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Knockdown, Migration, CCK-8 Assay, Control

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: Knockdown of RIG-I promotes A549 and H460 cells proliferation and migration, and IRF9 or IFI6 are downstream proteins regulated by RIG-I. (A, B) Colony formation was analyzed to detect the proliferation in control and RIG-I-KD A549 (A) or H460 (B) cells. (C, D) Transwell assays showed the ability of migration in control and RIG-I-KD A549 (C) or H460 (D) cells. (E) Heat map of RNA- seq to identify the genes regulated by METTL3 knockdown. (F, G) Westrern blot to detected RIG-I, IRF9 and IFI6 protein levels of control and METTL3-KD A549 (F) or H460 (G) cells. (H, I) Shown are RIG-I, IRF9 and IFI6 protein levels in A549 (H) or H460 (I) cells treated with DMSO and Inarigivir soproxil (5 μM) for 48 h. The data represents the mean±SD from three independent experiments.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Knockdown, Migration, Control, RNA Sequencing

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: Knockdown of METTL3 Increased the release of IFNα/β and enhanced the killing effect of T cells. (A, B) The IFNα (A) and IFNβ (B) concentration was measured using an enzyme-linked immunosorbent assay (ELISA) in A549 or H460 cells. (C-F) Microscopic observation and crystal violet staining after T-cell cytotoxicity assays were performed to evaluate the killing capability of in vitro T cells towards control and METTL3-KD A549 (C, D) or H460 (E, F) cells. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Knockdown, Concentration Assay, Enzyme-linked Immunosorbent Assay, Staining, In Vitro, Control

Journal: Translational Oncology

Article Title: m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway

doi: 10.1016/j.tranon.2024.102230

Figure Lengend Snippet: RIG-I was identified as a downstream target of METTL3. (A) Reatome annotations analysis (left) and KEGG pathway analysis (right) after METTL3 knockdown in A549 cells by RNA-seq. (B, C) RIG-I protein levels in control and METTL3- KD A549 (B) or H460 (C) cells by western blot analysis. (D, E) The mRNA expression of RIG-I in control and METTL3- KD A549 (D) or H460 (E) cells was detected by qRT - PCR. (F) The protien levels of the RIG-I-MAVS signaling pathway was detected after METTL3 knockdown in A549 and H460 cells. (G, H) The protein levels of RIG-I in METTL3-OV A549 (G) or H460 (H) cells by western blot analysis. The data represents the mean±SD from three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The antibodies were listed as below: Anti-METTL3 antibody (ABclonal, A19079), anti-RIG-I/DDX58 antibody (Proteintech, 20566-1-AP), anti-MAVS antibody (ABclonal, A5764), anti-GAPDH antibody (Proteintech, 10494-1-AP), anti-phospho-TBK1/NAK-S172 antibody (ABclonal, AP1026). anti-TBK1 antibody (proteintech, 67211-1-Ig), anti-phospho-IRF3-S386 antibody (ABclonal, AP0995), anti-IRF3 antibody (ABclonal, A19717). anti-YTHDF1 antibody (ABclonal, A23773), anti-YTHDF2 antibody (ABclonal, A15616), anti-YTHDF3 antibody (ABclonal, A8395), anti-IRF9 antibody (ABclonal, A21331), anti-IFI6 antibody (ABclonal, A6157), anti-phospho-NF-κB p65/Rel antibody (ABclonal, AP1294), anti-NF-κB (Cell Signaling Technology, #8242).

Techniques: Knockdown, RNA Sequencing, Control, Western Blot, Expressing, Quantitative RT-PCR

Journal: Biochimie

Article Title: Hypoxia-induced downregulation of RNA m 6 A protein machinery in the naked mole-rat heart.

doi: 10.1016/j.biochi.2024.05.017

Figure Lengend Snippet: Fig. 2. The expression levels of key proteins of the RNA m6A methylation machinery in normoxic vs. 24 h hypoxic H. glaber heart. Relative protein abundance of METTL3, METTL14, WTAP, ALKBH5, FTO, SRSF3, YTHDF1-3, and eIF3a were measured via Western immunoblotting. Data are displayed as mean band densities (±SEM, n ¼ 4e5) and were analyzed with a Student's t-test (p < 0.05). Values for hypoxic naked mole-rats that are statistically different from the corresponding control are denoted by an asterisk.

Article Snippet: Membranes were incubated with 1:1000 v:v primary antibody overnight at 4 C. The antibodies used were METTL3 (Abclonal; Cat. #: A8370), METTL14 (Cell Signaling; Cat. #: 51104T), WTAP (Cell Signaling; Cat. #: 56501T), SRSF3 (Abclonal; Cat. #: A6067), YTH N6-methyladenosine RNA binding protein 1 (YTHDF1; Abclonal; Cat. #: A13260), YTHDF2 (Abclonal; Cat. #: A15616), YTHDF3 (Abclonal; Cat. #: A8395), ALKBH5 (Abexa; Cat. #: abx125516), FTO (Novus Biologicals; Cat. #: NBP1-77021), VIRMA (Cell Signaling; Cat. #: 88558T), eIF3a (Abclonal; Cat. #: A0573) and YTH N6-Methyladenosine RNA Binding Protein C2 (YTHDC2; Abclonal; Cat. #: A15004).

Techniques: Expressing, Methylation, Quantitative Proteomics, Western Blot, Control